Transfusion-Related Cost and Time Burden Offsets in Patients with Myelofibrosis Treated with Momelotinib in the SIMPLIFY-1 and SIMPLIFY-2 Trials
Lucia Masarova, Tom Liu, Mirko Fillbrunn, Weilong Li, Gautam Sajeev, Sumati Rao, Boris Gorsh, James Signorovitch, Susan L Slager · 2024
Read Transfusion-Related Cost and Time Burden Offsets in Patients with Myelofibrosis Treated with Momelotinib in the SIMPLIFY-1 and SIMPLIFY-2 Trials by Lucia Masarova, Tom Liu, Mirko Fillbrunn, Weilong Li, Gautam Sajeev, Sumati Rao, Boris Gorsh, James Signorovitch, Susan L Slager (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11640613.txt.
Description
Nine authors present a cost study from two thousand twenty-four on a drug for a bone marrow disorder. Myelofibrosis often causes anemia, and blood transfusions to treat it burden patients with cost and time. The drug momelotinib was tested against standard care in two large trials, called SIMPLIFY-1 and SIMPLIFY-2.
The authors used the trials' twenty-four-week transfusion data plus cost figures from a United States claims database. They projected how transfusion costs and time would differ on the new drug. Patients were split by whether they needed transfusions at the start, and subgroups by anemia depth and age were checked too.
Catalog record
| CREATOR | Lucia Masarova, Tom Liu, Mirko Fillbrunn, Weilong Li, Gautam Sajeev, Sumati Rao, Boris Gorsh, James Signorovitch, Susan L Slager |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 43 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |